Asymmetric dimethylarginine (ADMA) and cardiovascular disease: insights from prospective clinical trials. - Wikidata - awgldk - TriplyDB

Asymmetric dimethylarginine (ADMA) and cardiovascular disease: insights from prospective clinical trials.

Asymmetric dimethylarginine (ADMA) and cardiovascular disease: insights from prospective clinical trials.

http://www.wikidata.org/entity/Q36381000

about

Asymmetric dimethylarginine and reactive oxygen species: unwelcome twin visitors to the cardiovascular and kidney disease tables Antiretrovirals induce endothelial dysfunction via an oxidant-dependent pathway and promote neointimal hyperplasia From arginine methylation to ADMA: a novel mechanism with therapeutic potential in chronic lung diseases Regulation of the ADMA-DDAH system in endothelial cells: a novel mechanism for the sterol response element binding proteins, SREBP1c and -2.Asymmetric dimethylarginine in angiotensin II-induced hypertension Asymmetric dimethylarginine: a novel cardiovascular risk factor in end-stage renal disease.A systematic review of metabolite profiling in gestational diabetes mellitus.Effects of rosuvastatin on ADMA, rhokinase, NADPH oxidase, caveolin-1, hsp 90 and NFkB levels in a rat model of myocardial ischaemia-reperfusion.Asymmetric dimethylarginine induces endothelial nitric-oxide synthase mitochondrial redistribution through the nitration-mediated activation of Akt1 Nitric oxide signaling in the microcirculation.Metabolomics reveals that tumor xenografts induce liver dysfunction.The relationship of nitric oxide synthesis capacity, oxidative stress, and albumin-to-creatinine ratio in black and white men: the SABPA study Evaluation of asymmetric dimethylarginine (ADMA) levels in children with growth hormone deficiency.Asymmetric dimethylarginine: a novel biomarker of gastric mucosal injury?Novel cardiac-specific biomarkers and the cardiovascular continuum.Novel Risk Stratification Assays for Acute Coronary Syndrome.Metabolomic Profiling of Arginine Metabolome Links Altered Methylation to Chronic Kidney Disease Accelerated Atherosclerosis.Plasma asymmetric dimethylarginine levels are increased in neonates with bronchopulmonary dysplasia-associated pulmonary hypertension Protective effect of CDP-choline on ischemia-reperfusion-induced myocardial tissue injury in rats.Comprehensive assessment of nephrotoxicity of intravenously administered sodium-oleate-coated ultra-small superparamagnetic iron oxide (USPIO) and titanium dioxide (TiO2) nanoparticles in rats.Asymmetric dimethylarginine in hematological malignancies: a preliminary study.The role of asymmetric dimethylarginine (ADMA) and leptin in hypertensive patients.Inhibition of human dimethylarginine dimethylaminohydrolase-1 by S-nitroso-L-homocysteine and hydrogen peroxide. Analysis, quantification, and implications for hyperhomocysteinemia.Anti-Atherogenic Activity of Polyphenol-Rich Extract from Bee Pollen.Biological variation of asymmetric dimethylarginine and related arginine metabolites and analytical performance goals for their measurement in human plasma.1H-NMR analysis of the human urinary metabolome in response to an 18-month multi-component exercise program and calcium–vitamin-D3 supplementation in older men Serum Asymmetric Dimethylarginine Concentrations in Two Models of Experimentally Induced Hypertension

P2860

Q26865426-478C9F9F-3C73-417D-86F9-972DC74B7A21 Q30430542-C39CD5D1-6579-4BB5-8214-B9476A6D85FF Q33403876-C0D1154F-A385-4241-B373-F597F72C9D01 Q33589158-CF966817-2733-424E-8EBE-D7F6C6D80BA3 Q33728163-50A3C102-DFFC-41FE-9199-D9F0EBC78F31 Q34201581-F14BDA4F-771D-4564-992D-CACDCA18E890 Q34458995-D7F029BD-80E6-49EE-8E29-A1A95C644F72 Q34562019-138F5999-FF40-4980-9DC7-CD0EC55AA93B Q36647252-765B5A0A-B328-46D0-8B52-37CBB84CFA91 Q36717720-8E22AD18-33B7-4813-9C65-A9CD34D931AA Q37072851-ADE5910A-4B19-4655-8E9F-FCC2AC5F3499 Q37219460-B975355E-DA55-40DF-B4E5-9A4CE6DFCDA3 Q37702780-13970E67-7180-49CA-A4EC-474FFD85EC7E Q37883913-94609CE4-AB7A-42F2-95E3-22630BB198F2 Q38009305-3E7F9269-49B9-4E2D-8A58-D79D08F44DC6 Q38666324-D31F1A74-693F-4A67-A643-B517EDD2592F Q41979223-83335D3C-31B6-4259-9745-BF8FF5C45627 Q42174480-7B183BC2-AA73-4F40-A082-0B28FF28C576 Q42450274-7D2FDAD8-685B-452C-A1D5-1FD84E4F0F49 Q43465717-83BB512D-2862-4BE4-9D89-79AB8AFAB3F1 Q46216898-26F0384E-A23E-455A-96DC-6C91CD7EDC75 Q46784655-105610E1-19CE-471E-9D4C-A812C344B5D7 Q46982143-CB492B0D-0256-4BFB-BDDA-ECFAD55A892D Q47156005-0BD4C4E7-A9B8-46A5-A3B4-79F6A450F84D Q53021614-2E0610EC-57EC-4D2B-9C79-22A369D71565 Q57834185-B0B81F55-2FFE-4583-9FDA-162864FB4730 Q58996231-53A9052A-8156-4B81-9205-C18418E3E5EC

P2860

Asymmetric dimethylarginine (ADMA) and cardiovascular disease: insights from prospective clinical trials.

http://www.wikidata.org/entity/Q36381000

description

2005 nî lūn-bûn

@nan

2005年の論文

@ja

2005年学术文章

@wuu

2005年学术文章

@zh-cn

2005年学术文章

@zh-hans

2005年学术文章

@zh-my

2005年学术文章

@zh-sg

2005年學術文章

@yue

2005年學術文章

@zh

2005年學術文章

@zh-hant

name

Asymmetric dimethylarginine (A ...... m prospective clinical trials.

@ast

Asymmetric dimethylarginine (A ...... m prospective clinical trials.

@en

type

label

Asymmetric dimethylarginine (A ...... m prospective clinical trials.

@ast

Asymmetric dimethylarginine (A ...... m prospective clinical trials.

@en

prefLabel

Asymmetric dimethylarginine (A ...... m prospective clinical trials.

@ast

Asymmetric dimethylarginine (A ...... m prospective clinical trials.

@en

P1433

Q36381000-9C84102B-7AA1-4EFA-BD65-D82DD43B44CD

P1476

Q36381000-22C902FB-4610-4BA1-868F-DC0B60D906D6

P2093

Q36381000-DE2B5328-AA41-43AD-96A1-541E10A4A428

P2860

Q36381000-057C012A-8DF6-4096-8237-54B6E7414972

Q36381000-09EDFFF3-9B28-4B79-B3B6-B1A971C97E6D

Q36381000-0C835F7E-F485-48B7-A37D-39748B54B7C9

Q36381000-1D8E059B-6A69-45EE-B53A-AAF98AA0FDB5

Q36381000-27AB43C8-9941-45DB-A4D6-18F114ECBDFE

Q36381000-27BBDF6F-C063-4A42-8484-839BFC3D2154

Q36381000-34CF9FCC-A939-4AFA-9AE3-7F0AD9E27E17

Q36381000-3DCFD786-7118-4FD4-8D73-4243C033C3C2

Q36381000-41F1EC70-B682-4487-B80C-43AC1742EC59

Q36381000-4448BA10-D27E-4A36-B067-F71DE957037A

P304

Q36381000-DDFE5634-7651-46BA-90E0-F96C9619ED12

P31

Q36381000-99F77893-8EDE-440F-9B30-CC5D5F2779E1

P356

Q36381000-E34C8439-B200-4F86-85A4-469E7CFEE9F3

P478

Q36381000-E6F71BB3-A408-477C-924A-80D6085AA3BA

P577

Q36381000-61EBCA10-0C9D-4AF5-B250-521BD77EB5B2

P698

Q36381000-761ACBAD-CC43-4440-9199-7F5FA79A2369

P921

Q36381000-833DB94E-B7D0-4DA6-9203-D37CA7BD64D3

P356

1358863X05VM602OA

P1433

Vascular Medicine

P1476

Asymmetric dimethylarginine (A ...... m prospective clinical trials.

@en

P2093

Rainer H Böger

http://www.w3.org/2001/XMLSchema#string

P2860

Plasma asymmetric dimethylarginine modifies the effect of pravastatin on myocardial blood flow in young adults

Reduced urinary excretion of nitric oxide metabolites and increased plasma levels of asymmetric dimethylarginine in men with essential hypertension

Asymmetrical dimethylarginine: the Uber marker?

Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors.

The emerging role of asymmetric dimethylarginine as a novel cardiovascular risk factor.

Cardiovascular biology of the asymmetric dimethylarginine:dimethylarginine dimethylaminohydrolase pathway.

Acute systemic inflammation impairs endothelium-dependent dilatation in humans.

Accumulation of endogenous inhibitors for nitric oxide synthesis and decreased content of L-arginine in regenerated endothelial cells.

Asymmetric dimethylarginine (ADMA): a novel risk factor for endothelial dysfunction: its role in hypercholesterolemia.

Plasma levels of asymmetrical dimethyl-L-arginine in patients with congenital heart disease and pulmonary hypertension.

P304

S19-25

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1191/1358863X05VM602OA

http://www.w3.org/2001/XMLSchema#string

P478

10 Suppl 1

http://www.w3.org/2001/XMLSchema#string

P577

2005-07-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

16444865

http://www.w3.org/2001/XMLSchema#string

P921

cardiovascular disease